On March 20, a patent boundary dissolves in India, and nearly fifty pharmaceutical companies stand ready to cross it — among them Mankind Pharma, which sees in semaglutide not merely a product opportunity but a chance to redefine how chronic disease is treated across a vast and underserved population. The drug, long associated with affluent weight-loss markets abroad, may now find its way into smaller Indian towns and rural clinics, carried there by a company betting that speed, affordability, and existing trust with physicians will matter more than novelty. What unfolds is less a product laun
Mankind Pharma eyes early semaglutide entry as patent expires
Expanded access to semaglutide therapy for obesity and chronic disease patients across India, particularly in underserved non-metro markets.
This is not about a single product launch, but shaping a new chronic care category
Mark
Why does Mankind need to move so quickly here? The patent expires, the market opens—won't there be time to plan carefully?
Mimi
Speed matters because the first movers establish relationships with doctors and patients. Once a patient starts on a generic semaglutide from one manufacturer, switching is friction. Mankind's advantage is its existing network—they already have trust with diabetes specialists. If they wait, competitors will build those relationships first.
Mark
But they're saying they'll price it carefully, not just undercut everyone. That seems to contradict the rush.
Mimi
It's not a contradiction. They want to be first, but not at any cost. If they price too low, they can't sustain supply or quality. The real win is being first at a price that works—not the cheapest, but cheaper than what exists now, and available everywhere, not just in cities.
Mark
You mentioned obesity is now a chronic disease. That's a shift from how people used to think about it.
Mimi
It is. Semaglutide proved that obesity responds to medical treatment the way diabetes does. Once that happened, cardiologists started prescribing it because obesity drives heart disease. Orthopedists prescribed it because weight affects joints. The drug didn't change—our understanding of what it treats did. That's why the market is suddenly so large.
Mark
The company went through a rough integration. How does that affect their ability to execute this launch?
Mimi
It's a real question. They say they've stabilized, that the restructuring is complete. But launching a major new product while you're still integrating an acquisition is complicated. You need field teams aligned, supply chains working, manufacturing capacity ready. If those pieces aren't solid, a fast launch becomes a messy one.
Mark
What happens to patients if Mankind gets this right?
Mimi
Semaglutide becomes available at a fraction of current prices across India, not just in Delhi or Mumbai. A patient in a smaller city who couldn't afford the drug suddenly can. That's the human dimension—access expands dramatically. But it only happens if Mankind executes and prices it in a way that actually reaches those patients.
Le Pouls
- A single date — March 20 — triggers a race among roughly fifty generic manufacturers to claim ground in one of the most consequential drug markets of the decade.
- Semaglutide's reach has expanded far beyond diabetes into cardiology, orthopedics, and gynecology, meaning the competitive stakes extend across multiple medical specialties simultaneously.
- Mankind is moving without partners, staking its first-mover ambition entirely on its own distribution network and physician relationships built through years in the diabetes market.
- Pricing remains the unresolved tension at the center of everything — the drug is costly to manufacture, yet affordability is the very promise Mankind has built its reputation upon.
- The company enters this race still absorbing the disruption of a major acquisition, having spent the past year restructuring its workforce, realigning its portfolio, and stabilizing its operations.
- If Mankind executes, the trajectory points toward a broader chronic care platform — nutraceuticals, biosimilars, specialty injectables — reshaping what kind of company it intends to become.
On March 20, a patent boundary dissolves in India, and nearly fifty pharmaceutical companies stand ready to cross it — among them Mankind Pharma, which sees in semaglutide not merely a product opportunity but a chance to redefine how chronic disease is treated across a vast and underserved population. The drug, long associated with affluent weight-loss markets abroad, may now find its way into smaller Indian towns and rural clinics, carried there by a company betting that speed, affordability, and existing trust with physicians will matter more than novelty. What unfolds is less a product launch than a test of whether access to transformative medicine can be democratized at scale.
On March 20, a patent expires in New Delhi, and Mankind Pharma intends to move through the opening it creates without hesitation. Semaglutide — a drug that transformed weight loss conversations in wealthier countries — has remained largely inaccessible to most Indians. With nearly fifty generic manufacturers preparing to enter the market simultaneously, Mankind's vice chairman Rajeev Juneja has staked out a clear position: launch fast, price aggressively, and do it independently.
What gives this moment weight is what semaglutide has become. Developed originally for diabetes, it has since drawn prescriptions from cardiologists, orthopedic surgeons, and gynecologists. The global market for this class of drug is projected to reach tens of billions of dollars. India, with its rising rates of obesity and metabolic disease and its enormous population, represents an opportunity that has barely been touched.
Mankind's existing diabetes business — ranked among India's top five pharmaceutical franchises — provides the foundation. The company knows how to reach patients with chronic conditions, how to navigate a fragmented market, and how to extend its distribution from major cities into smaller towns. Juneja framed the semaglutide launch not as a single product event but as the opening of an entirely new chronic care category in India.
The pricing question remains genuinely unresolved. Semaglutide is complex and expensive to produce, yet affordability is central to Mankind's identity. Juneja acknowledged the tension carefully, describing pricing as a strategic decision still under evaluation — one that must balance accessibility against the margins needed to sustain long-term supply.
The company has also been navigating internal turbulence. The past year brought significant disruption following its acquisition of specialty firm BSV — restructuring, portfolio realignment, field force consolidation. Juneja described it as deliberate structural strengthening, and says the integration is now largely complete, with volume growth beginning to stabilize.
Looking further out, Mankind is building toward biosimilars and complex specialty injectables, longer-term bets that signal a company trying to move toward higher-value therapies. When the patent lifts, fifty competitors will flood in together. Whether Mankind's infrastructure, its physician trust, and its reach beyond urban centers prove decisive will depend on execution — and on how quickly India comes to treat obesity and metabolic disease as chronic conditions worthy of sustained medical attention.
On March 20, a patent expires in New Delhi, and with it comes an opening that Mankind Pharma intends to move through quickly. The drug is semaglutide—a treatment that has become synonymous with weight loss in wealthy countries, but which remains largely out of reach for most Indians. Nearly fifty generic manufacturers are preparing to flood the market once the patent protection lifts. Mankind, India's fourth-largest pharmaceutical company, wants to be among the first to arrive.
Rajeev Juneja, the company's vice chairman and managing director, laid out the strategy in measured terms: move fast, price aggressively, and do it alone. No partnerships, no co-marketing arrangements with other firms. The company will handle the launch independently, betting that its existing relationships with doctors and its distribution network—stretching from major cities into smaller towns and rural areas—will give it an edge. "We expect to be among the first wave of launches," Juneja said, framing the move as part of a larger commitment to making high-quality therapies accessible to patients who might otherwise never afford them.
What makes this moment significant is not just the patent expiry itself, but what semaglutide has become. Originally developed as a diabetes treatment, the drug has revealed a much larger market. Obesity is now recognized as a chronic health crisis, and semaglutide works for that too. Cardiologists are prescribing it. Orthopedic surgeons see its value. Gynecologists recommend it. The global market for this class of medicine is estimated to reach tens of billions of dollars over the next few years. India, with its massive population and rising rates of obesity and metabolic disease, represents a fraction of that opportunity that has barely been tapped.
Mankind's diabetes business already ranks in the top five across India's pharmaceutical market, consistently outperforming the broader industry. That foundation matters. The company understands how to reach patients with chronic conditions, how to work with specialists, how to build trust in a fragmented market. Juneja emphasized that this is not about launching a single product and moving on. "This is not about a single product launch, but about helping open and shape a new chronic care category in India," he said. The company is simultaneously exploring adjacent markets—nutraceuticals, multivitamins, protein supplements—all aimed at building a more comprehensive chronic care offering.
The pricing question hangs over everything. Mankind has built its reputation on affordability, but semaglutide is complex and expensive to manufacture. Juneja acknowledged the tension without resolving it: "Pricing is a strategic decision, and we are evaluating it carefully to ensure both accessibility and long-term sustainability." The company will need to find a price point that makes the drug available to more Indians than it currently is, while still generating enough margin to justify the investment and ongoing supply.
The company has also been through a difficult period. The past year brought integration challenges following its acquisition of BSV, a specialty pharmaceutical firm. There was organizational restructuring, portfolio realignment, field force consolidation. Juneja characterized it as a "deliberate phase of structural strengthening," a period of short-term pain for long-term gain. The company upgraded its talent pool, improved its processes through digitization, and realigned its product portfolio. He says the integration is now substantially complete and that volume growth is beginning to stabilize.
Looking further ahead, Mankind is also preparing to enter the biosimilars space—complex biological drugs that are cheaper versions of existing biologics. Through its partnerships with global companies, including manufacturers in China, the firm is building capabilities in specialty injectables and complex generics. These are longer-term bets, dependent on regulatory approvals and manufacturing readiness, but they point toward a company trying to shift itself toward higher-value, more specialized therapies.
When the patent expires on March 20, the market will open. Fifty generic versions will compete on price and availability. Mankind will be one of them, but it is betting that its existing infrastructure, its diabetes expertise, and its commitment to reaching patients beyond metro areas will matter. Whether that proves true will depend partly on how aggressively it prices, partly on how well it executes, and partly on how quickly obesity and metabolic disease become recognized as chronic conditions worth treating across all of India, not just in wealthy urban centers.
Citations marquantes
We expect to be among the first wave of launches. Our approach remains disciplined, with a strong focus on quality, accessibility, and long-term value creation.— Rajeev Juneja, vice chairman and managing director, Mankind Pharma
Pricing is a strategic decision, and we are evaluating it carefully to ensure both accessibility and long-term sustainability.— Rajeev Juneja, Mankind Pharma
Envie de l'histoire complète ?
Lire l'original sur The Economic Times ↗
Health & Medicine